Home › Type 1 Diabetes › NCT04449198
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
RecruitingEarly phase 1Healthy volunteers welcome
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Men and premenopausal women * All races * Clinical diagnosis of insulin-dependent type 1 diabetes (patients only) Exclusion Criteria: * Clinical diagnosis of hepatic, cardiovascular, or renal disease * Uncontrolled diabetes (HbA1C \>12%) * Diabetic complications (i.e. neuropathy) * Uncontrolled hypertension (\>140/90 mm Hg on therapy) * Pregnancy * Use of vasoactive medications
About the study
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
What is being tested
- Resveratrol (drug)
- Placebo (other)
Sponsor: Augusta University · Participants: 24 · Started: Oct 14, 2020
Contact the study team
- Ryan A Harris, PhD, CEP · Phone: 7067215998
- Jacob Looney, MS · Phone: 7067215483
Official record on ClinicalTrials.gov — NCT04449198
Locations in the U.S.
| Georgia | Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.